Leadership team

LGC’s board and executive management teams have an extensive understanding of the scientific marketplaces we serve. They are committed to supporting and creating opportunities for our employees worldwide, delivering high quality performance and services for our customers.

Board of directors

Tim Robinson CBE - Chief Executive Officer
Tim Robinson

Tim Robinson CBE - Chief Executive Officer

Tim joined LGC in 2013 as Chief Executive.

Tim has followed an international career in the technology and services sectors, spanning Engineering, Marketing and Corporate Leadership. Following a decade with IBM in Asia and Europe where he finished as a Director of IBM UK, Tim held senior executive positions in Silicon Graphics (SGI) and Thales, prior to being CEO for Xafinity, the privatised Office of the Paymaster General, and subsequently to Talaris (ex De La Rue).
 
Tim is a Non-Executive Director of the UK Government Department for International Development. He has also been a Non-Executive Board Member of UK Trade & Investment, a Member of the Association of Oxfam, serving on their Audit Committee, and a Non-Executive Director of Camelot Group.

Tim was awarded a CBE in the 2020 New Year’s Honours list for his advisory role in a personal capacity for the UK Government.

Simon Parsons - Chief Financial Officer
Simon Parsons

Simon Parsons - Chief Financial Officer

Simon was appointed Chief Financial Officer of LGC on 4 October 2010. He joined LGC after working as CFO in two private equity investments owned by Apax Partners and Balderton Capital. Prior to that, Simon held a number of General Manager and Finance Director positions in the UK and Italy with Celesio AG, a leading European wholesale and retail pharmaceuticals business. He qualified with Ernst & Young in 1993 where he worked in the UK and US practices.

Dr Derek Craston - Chief Scientific Officer

Dr Derek Craston - Chief Scientific Officer

Derek Craston joined the LGC Board on 1 February 2012 as LGC's Chief Scientific Officer.  He continues with his existing role leading LGC's Health Science & Innovation division.

Derek's responsibilities as CSO include leading the scientific effort of the company, coordinating science development across the business and developing our scientific partnerships for research, discovery and innovation. Derek was Government Chemist from June 2008 - May 2018.

Euan O’Sullivan - Chief Operating Officer
Euan

Euan O’Sullivan - Chief Operating Officer, LGC

Having initially joined LGC as a Non-Executive Director in late 2007, Euan O’Sullivan assumed an executive role as Corporate Development Director in July 2010. He was subsequently appointed Managing Director of the Standards division in July 2012, joined LGC’s Board as an Executive Director in 2017 and became Chief Operating Officer, with responsibility for leading all of LGC’s divisions, in June 2020.

Euan joined LGC from UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to LGC, Euan worked as a consultant in Accenture’s business strategy practice and within the M&A division of Close Brothers Corporate Finance. Euan is a graduate of University College, Oxford.

Tish S Creasey, Ph.D. - Non Executive Director

Tish S Creasey, Ph.D. - Non Executive Director

Tish joined the Board in August 2020.  Prior to joining the Group, Tish served as the Execute Vice President of Applied Solutions Strategy, Marketing and Innovation (SMI) for MilliporeSigma, a Merck KGaA Company.  Before the acquisition of Sigma-Aldrich by Merck KGaA, Tish was part of Sigma-Aldrich from 2005 – 2015 and served as Vice President of Diagnostics & Testing team as well as Vice President of Global Custom Products business focused on oligonucleotides and peptides. 

Prior to joining Sigma-Aldrich, Tish was with Applied Biosystems from 1999-2005 and served as Director, R&D Proteomics & Small Molecule Division with a focus in Mass Spectrometry.  Tish has enjoyed a career directing multidisciplinary product development in the life science and pharmaceutical markets and a successful track record managing in both global multinational environments and small entrepreneurial settings. 

Professionally, Tish is the recipient of several scientific achievement awards; she is a published author of both scientific articles and patents.  Tish completed her Ph.D. in Organic Chemistry from The Pennsylvania State University, State College, Pennsylvania, USA. 

James Davis - Non Executive Director

James Davis - Non Executive Director

James Davis joined Astorg in 2019 and is a member of the investment team.

Prior to this, James spent 20 years at ICG where he was Managing Director responsible for investments in the Nordic Region and a member of the Investment Committee.

James started his career at Deloitte where he qualified as a chartered accountant.

James is a graduate of Oxford University

François de Mitry - Non Executive Director

François de Mitry - Non Executive Director

François de Mitry joined Astorg in 2012 and is a member of the Investment team.

He has been involved in a number of transactions including MEGADYNE, LINXENS, IQ-EQ, FLOWBIRD, AUDIOTONIX and ANAQUA.

Prior to this, François was with Intermediate Capital Group PLC from 1997. He was appointed Managing Director in 2005, then became progressively responsible for ICG's investment activities in Mezzanine and Equity worldwide.

Previously, he was an Associate Director at the LBO division of Société Générale in London.

He began his carrier at the M&A division of HSBC in London.

François graduated from Institut d'Etudes Politiques de Paris and Université de Dauphine Paris IX

Matthew Norton - Non Executive Director

Matthew Norton

Matthew is a member of Cinven’s Healthcare sector team. He has been involved in a number of transactions, including Medpace, NPS, Pronet, Sebia, STADA, Labco and Synlab (merged under the Synlab brand), Envirotainer and Ufinet.

Prior to joining Cinven, Matthew worked in the Investment Banking Division of Citigroup in London, advising on M&A and restructuring deals across a range of sectors including consumer, real estate, TMT and healthcare.

Matthew graduated from Imperial College London with an MSc in Physics.

He joined Cinven in 2010

Supraj Rajagopalan - Non Executive Director

Supraj Rajagopalan - Non Executive Director

Supraj leads Cinven’s Healthcare Sector team. He sits of the firm’s Investment and Executive Committees. He has worked on a number of transactions, including Ahlsell, Barentz, Bioclinica, CeramTec, JLA, Medpace, National Seating & Mobility, Phadia, Sebia and STADA. 

Previously, he was at The Boston Consulting Group, where he worked on projects in the healthcare and financial services sectors. 

Supraj graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences. 

He joined Cinven in 2004

Dr Nicolas Roelofs - Non Executive Director
Nicholas Roelofs

Dr Nicolas Roelofs - Non Executive Director

Nicolas joined the Board in April 2016. Prior to joining the Group, Nicolas served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group from 2009 to 2013. He also served as the Vice President and General Manager of the Life Sciences division from 2006 to 2009.

Prior to joining Agilent Technologies Inc., Nicolas was with Bio-Rad Laboratories, Inc. from 2005 to 2006 and served as the Life Science Group’s Group Operations Officer heading five business divisions spanning life science and food science. His time at Stratagene Corporation from 2001 to 2005 saw him serve as Senior Vice President of marketing, sales and business development for the first two years and as Chief Operating Officer for the last two years.

Professionally, Nicolas is a Global 50 Member and also a part of the Malaysian Biotechnology International Advisory Panel. He has also served on the Advisory Board of Chemical & Engineering News for the American Chemical Society Magazine. Nicolas completed his M.S. in Organic Chemistry from Iowa State University and has a PhD in Organic Chemistry from the University of Nevada, Reno.

 

Executive leadership team

Tim Robinson CBE - Chief Executive Officer
Tim Robinson

Tim Robinson CBE- Chief Executive Officer

Tim joined LGC in 2013 as Chief Executive.

Tim has followed an international career in the technology and services sectors, spanning Engineering, Marketing and Corporate Leadership. Following a decade with IBM in Asia and Europe where he finished as a Director of IBM UK, Tim held senior executive positions in Silicon Graphics (SGI) and Thales, prior to being CEO for Xafinity, the privatised Office of the Paymaster General, and subsequently to Talaris (ex De La Rue).
 
Tim is a Non-Executive Director of the UK Government Department for International Development. He has also been a Non-Executive Board Member of UK Trade & Investment, a Member of the Association of Oxfam, serving on their Audit Committee, and a Non-Executive Director of Camelot Group.

Tim was awarded a CBE in the 2020 New Year’s Honours list for his advisory role in a personal capacity for the UK Government.

Simon Parsons - Chief Financial Officer
Simon Parsons

Simon Parsons - Chief Financial Officer

Simon was appointed Chief Financial Officer of LGC on 4 October 2010. He joined LGC after working as CFO in two private equity investments owned by Apax Partners and Balderton Capital. Prior to that, Simon held a number of General Manager and Finance Director positions in the UK and Italy with Celesio AG, a leading European wholesale and retail pharmaceuticals business. He qualified with Ernst & Young in 1993 where he worked in the UK and US practices.

Dr Derek Craston - Chief Scientific Officer

Dr Derek Craston - Chief Scientific Officer

Derek Craston joined the LGC Board on 1 February 2012 as LGC's Chief Scientific Officer.  He continues with his existing role leading LGC's Health Science & Innovation division.

Derek's responsibilities as CSO include leading the scientific effort of the company, coordinating science development across the business and developing our scientific partnerships for research, discovery and innovation. Derek was Government Chemist from June 2008 - May 2018.

Euan O’Sullivan - Chief Operating Officer, LGC
Euan

Euan O’Sullivan - Managing Director, LGC Standards

Having initially joined LGC as a Non-Executive Director in late 2007, Euan O’Sullivan assumed an executive role as Corporate Development Director in July 2010. He was subsequently appointed Managing Director of the Standards division in July 2012, joined LGC’s Board as an Executive Director in 2018 and became Chief Operating Officer, with responsibility for leading all of LGC’s divisions, in June 2020.

Euan joined LGC from UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to LGC, Euan worked as a consultant in Accenture’s business strategy practice and within the M&A division of Close Brothers Corporate Finance. Euan is a graduate of University College, Oxford.

Lisa Amaya Price - Chief People Officer

Lisa Amaya Price - Chief People Officer

Lisa Amaya Price joined LGC in October 2020, as Chief People Officer.

Lisa’s experience of working with Life Sciences companies includes Takeda Pharmaceuticals, where she led the organisational design and talent selection related to the company’s acquisition of Shire Pharmaceuticals and was Global Head of Human Resources for Takeda’s vaccine business unit.  Before joining Takeda, Lisa served in various positions of increasing responsibility at Biogen, Inc. from 2008 to 2016. 

Most recently, prior to joining LGC, Lisa was SVP, Human Resources at Scholar Rock, Inc. a clinical-stage biotechnology company based in Massachusetts.

Lisa holds an MBA from F.W. Olin Graduate School of Business at Babson College, an M.A. from Simmons College, and a B.A. from Bard College.

Dr Frances Crummay - Chief Information Officer

Dr Frances Crummay - Chief Information Officer

Frances Crummay joined LGC in September 2011 and was promoted to Chief Information Officer (CIO) in January 2014. Her responsibilities cover the full range of global IT operations including IT strategy, policy, security and disaster recovery. She is responsible for ensuring the effective delivery of IT services and digital communications across the operational and scientific communities with the strategic intention of putting innovation and technology at the heart of LGC’s business.
 
Frances has a PhD and started her career at the Met Office. She has run complex IT systems and services for a variety of companies including Zurich Insurance, Businesslink.gov.uk and DSTL (Defence, Science and Technology Laboratory).

Mark Dearden - Managing Director, LGC Genomics

Mark Dearden - Managing Director, LGC Genomics

Having initially joined LGC as a BU Director in 2011, Mark Dearden went on to serve as Vice President of Strategy and Marketing for the Genomics Division. In this role, Mark was responsible for the Division’s M&A activities, partnering, organic product development and marketing communications activities. Mark was appointed as Managing Director of the Genomics Division in July 2020.

Prior to LGC, Mark has held diverse International leadership positions in General Management, Marketing, Product Management and Sales with leading life sciences companies such as GE Healthcare and Thermo Scientific.  Mark has a BSc (honours) from University of Sydney and an MBA from Warwick Business School.

Michael Dubois - Head of Corporate Development
Michael Dubois

Michael Dubois - Corporate Development Director

Michael joined LGC in 2011 and leads the Group’s corporate development activities, including mergers, acquisitions, disposals and strategy development. Prior to joining LGC, Michael was at Close Brothers Corporate Finance where he was a Managing Director in the firm’s M&A team. Michael holds an M.A. (First Class Hons) in Natural Sciences, specialising in organic chemistry, from the University of Cambridge

Greer McMullen - General Counsel and Company Secretary

Greer McMullen - General Counsel and Company Secretary

Greer McMullen joined LGC in September 2020, as General Counsel and Company Secretary.

Greer has a wealth of experience spanning executive roles in a number of companies, including GE, The Service Master Company and most recently Coty Inc. 

Greer has operated across a number of different geographies and cultures, in the Americas, Europe and Asia Pacific. Greer was educated in the UK and France before attending university in the US at Georgetown University School of Foreign Service and then law school at the University of Virginia School of Law.  He is a member of Virginia Bar and is an avid fencer when time permits.

Michael Sweatt - Executive Vice President and General Manager, Clinical Diagnostics Division

Michael Sweatt - Executive Vice President and General Manager, Clinical Diagnostics Division

Michael was appointed executive VP and general manager in 2018, following the acquisition of SeraCare Life Sciences and subsequently joined LGC’s executive leadership team in 2020.

Michael joined LGC in 2015 as the General Manager and Chief Operating Officer of Maine Standards Company.

Michael has over 35 years of commercial, sales, and management experience in the in vitro diagnostic industry. Early in his career, he was the Chief Assistant Medical Technologist in the Pathology and Laboratory Medicine department at Maine Medical Center and later transitioned into sales management roles for CASCO Standards, Microgenics, and Fisher Scientific., Michael also served as the Executive Vice President and Chief Operating Officer for a privately held chemical standards manufacturer in the environmental and food safety industry.

Jon Yeung - Managing Director, LGC Standards
Jon Yeung

Jon Yeung - Managing Director, LGC Standards

Jon was appointed Managing Director, LGC Standards in July 2020.

Jon joined LGC in 2011 as Group Financial Controller. He subsequently became Group Finance director in 2014 and then Managing Director of LGC Forensics in 2016 and Chief Operating Officer at LGC Standards in 2017.

Before joining LGC, Jon worked at PwC in a variety of commercial and operational roles in the UK and US in the life science, pharma and broader industrial sectors. Jon is a qualified chartered accountant and member of the ICAEW, holding an MA (Oxon) from Wadham College, Oxford University.


Science advisory board

Dr Laurie Locascio - Chair, University of Maryland

Dr Laurie Locascio - Chair, University of Maryland

Laurie E. Locascio, Ph.D., is the Vice President for Research at the University of Maryland.

Previously Laurie worked at the National Institute of Standards and Technology (NIST) in Gaithersburg, MD, rising from a research biomedical engineer to senior leadership positions, including most recently, Acting Principal Deputy Director and Associate Director for Laboratory Programs, providing leadership and operational guidance for NIST's seven scientific and mission-focused laboratories.

Laurie's most recent honors and awards include the 2017 American Chemical Society Earle B. Barnes Award for Leadership in Chemical Research Management, and the 2017 Washington Academy of Sciences Special Award in Scientific Leadership.  She has published 115 scientific papers and holds 11 patents in the fields of bioengineering and analytical chemistry. Laurie is a Fellow of the American Chemical Society (ACS) and the American Institute for Medical and Biological Engineering (AIMBE).

Dr Ron Cook - Advisor

Dr Ron Cook - Advisor

Dr Ron Cook, is an entrepreneurial scientist focused on the development, application and commercialisation of synthetic nucleic acids. 

Ron has a Chemistry degree from UC Berkeley, a PhD from the University of Washington, Seattle, Department of Chemistry, and postdoctorate from the University of California, San Francisco, Department of Microbiology and Immunology.

Ron founded Biosearch, Inc in 1977 to supply synthetic peptides and protein bioconjugates to the research community. In 1980, the production of synthetic nucleic acids propulsed the company to become a leading innovator in oligonucleotide chemistry and a leader in the supply and technology development for synthetic DNA.  In 1982, the company developed the first commercially viable oligo synthesizer (SAM I), which enabled the invention of PCR in 1983. Over the next 30 years, under Ron’s leadership, Biosearch or its descendent entities, participated in the development of many oligo-driven technologies, including PCR, therapeutic antisense oligos, synthetic gene manufacture, sequencing of the human genome, si-RNA, and recently, fluorescent probes for genomic analysis and qPCR.   

Ron has published over 30 scientific papers and issued more than 25 patents. Today, Ron is chairman of a number of organisations in the US, Denmark and Germany. He is also co-founder and chairman of Optical Biosystems.

Prof. Duncan Graham - University of Strathclyde

Prof. Duncan Graham - University of Strathclyde

Duncan Graham is the Research Professor of Chemistry and Head of Department for Pure and Applied Chemistry at the University of Strathclyde in Glasgow. 

Duncan obtained his BSc Honours and PhD in Chemistry from the University of Edinburgh before joining the University of Strathclyde in 1996. He is Editor in Chief of the RSC journal Analyst and serves several editorial advisory boards including Chemical Society Reviews and Chemical Science.

Duncan is president of the analytical division of the Royal Society of Chemistry and chair of the analytical chemistry trust fund. He has published over 250 papers with 16 patents and has supervised over 60 PhD students and 35 postdoctoral researchers.

Duncan’s scientific interests are in using synthetic chemistry to produce sensors that respond to a specific biological species or events as measured by Raman spectroscopy or SERS. 

 

 

Dr Sven Kili – Consultant

Dr Sven Kili – Consultant

Sven provides Strategic consulting services to Cell and Gene Therapy organisations focused on business strategy, R&D, Clinical Development and commercial planning.

Prior to heading his own consultancy, Sven was VP and Development Head for the Gene and Cell Therapy division of GSK where he led the teams developing ex-vivo Gene Therapies for a variety of genetic disorders. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development and medical affairs activities culminating in the granting of the first combined ATMP approval in the EU for MACI®. Before joining Genzyme, Sven worked for Geistlich Pharma where, in addition to leading the cell therapy clinical and medical activities, he oversaw all UK & Ireland regulatory functions and was the QPPV for the EU.

Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practice, has grown his expertise all aspects of Cell and Gene Therapy. In addition to his consulting role, he has a number of other roles, including Board member for CCRM in Canada, Board member for Xintela A.B, Visiting Professor and Steering Committee chair for UCL Cell & Gene Therapy MSc and Chair of the BioIndustry Cell & Gene Therapy Advisory Committee. Sven also serves on specialist committees for the SCB, ASGCT and Alliance for Regen Med. He still maintains his clinical skills in the UK NHS and serves as an ATLS Instructor in his spare time. 

Dr Gene Yeo - University of California, San Diego

Dr Gene Yeo - University of California, San Diego

Dr. Gene Yeo is an expert in the areas of RNA biology and therapeutics, computational biology, genomics and neurological diseases.

Gene is a Professor of Cellular and Molecular Medicine at the University of California, San Diego (UCSD). He has a BSc in Chemical Engineering and a BA in Economics from the University of Illinois, Urbana-Champaign, a Ph.D. in Computational Neuroscience from Massachusetts Institute of Technology and an MBA from the UCSD Rady School of Management.

Gene’s research interest is in understanding and manipulating RNA processing in development and disease using induced pluripotent stem cell and murine models. His lab demonstrated in vivo RNA targeting with CRISPR/Cas proteins with proof of concept in repeat expansion disorders. Gene’s lab developed enhanced CLIP for the purposes of large-scale mapping of protein-RNA interactions. His lab is an active participant in RNA genomics technology and therapeutics development.

Gene is on the Editorial Boards of the journals Cell Reports and Cell Research. He is a recipient of Alfred P Sloan Fellowship in recognition of his work in computational molecular biology (2011) and the inaugural Early Career Award from the International RNA Society (2017).

Gene is a co-founder of several biotech companies including Locana, Eclipse Bioinnovations, Enzerna and Proteona. He serves or had served on the scientific advisory boards of the Allen Institute of Immunology, Locana, Eclipse Bioinnovations, Proteona, Aquinnah, LGC, Nugen and Ribometrix.